This newly developed animal model now includes three major hallmarks Depsipeptide of AD: genetically related age-dependent β-amyloidosis and tau hyperphosphorylation, complemented with experimentally induced cholinergic cell loss. Prospectively, such an attempt using 3xTg mice with modifiable cholinergic dysfunction appears promising for studies addressing different aspects of this devastating disease. Currently, acetylcholinesterase
inhibitors are still, despite their limitations, the most widely used drugs for symptomatic AD therapy [81]. Selective α7 nicotinic acetylcholine receptor partial agonists are now in clinical trials and have been demonstrated to be beneficial in preclinical studies by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors [82]. The presented data support the view that drugs targeting the cholinergic neurotransmission remain justified as a potential treatment strategy of AD (for review see [47]). The authors thank Drs Reinhard Schliebs and Thomas Arendt for critical reading of an earlier version from this article. We are
thankful to Dr Peter Davies (Pathology, Albert LEE011 mw Einstein College of Medicine, New York, USA), Dr Sascha Weggen (Neuropathology, University of Düsseldorf, Germany) and Dr Christian Czech (Hoffmann-La-Roche, Basel, Switzerland) for the donation of antibodies and Drs Frank M. LaFerla and Salvatore Oddo (University of California, Irvine, CA, USA) for pairs of triple-transgenic and WT mice. The technical assistance of Dr Anke Hoffmann, Ute Bauer and Marita Heindl is gratefully acknowledged. The biochemical part of the study was supported by the Alzheimer Forschung Initiative e.V. (to O.W.). The study was designed by Wolfgang Härtig who also performed the histological work together with Simone Goldhammer (SG) as part of her MD thesis. Immunolesions were made by Johannes Kacza. All biochemical data were generated by Annika Saul and Oliver Wirths. Histological CHIR-99021 cost figures were produced by Jens Grosche, Simone Goldhammer and Dominik Michalski. The manuscript was written
by Wolfgang Härtig and considerably improved by Oliver Wirths and Dominik Michalski. “
“Upon denervation, skeletal muscle fibres initiate complex changes in gene expression. Many of these genes are involved in muscle fibre remodelling and atrophy. Amyotrophic Lateral Sclerosis (ALS) leads to progressive neurodegeneration and neurogenic muscular atrophy. Disturbed calcium homeostasis and misfolded protein aggregation both in motor neurons and muscle fibres are key elements of ALS pathogenesis that are mutually interdependent. Therefore, we hypothesized that the calcium sensor STIM 1 might be abnormally modified and involved in muscle fibre degeneration in ALS and other types of NMA. We examined ALS and NMA patient biopsy and autopsy tissue and tissue from G93A SOD1 mice by immunohistochemistry and immunoblotting.
No related posts.